Last reviewed · How we verify
Menaquinone
Menaquinone, developed by Cairo University, is a marketed drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but the patent expiry presents a significant period of exclusivity. The lack of detailed revenue and competitive landscape data poses a primary risk in assessing its market strength and potential threats.
At a glance
| Generic name | Menaquinone |
|---|---|
| Also known as | vitamin k2 (Menaquinone), Vitamin k2 |
| Sponsor | Cairo University |
| Target | Aldehyde oxidase, Alpha-synuclein, Dual specificity phosphatase Cdc25A |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
- Constipation
- Dyspepsia
- Abdominal Pain
Key clinical trials
- OPTIA-AF Trial: Rhythm-Guided Antithrombotic Strategy After AF Ablation (PHASE4)
- FENOX Trial (Comparative Effectiveness of Fexuprazan Co-therapy in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants) (NA)
- SIMPLAAFY Clinical Trial (NA)
- A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)
- SWITCH: Apixaban vs Vitamin K in HM3 (PHASE3)
- A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer (PHASE1)
- CHAMPION-AF Clinical Trial (NA)
- Anticoagulation in Patients With Venous Thromboembolism and Cancer
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Menaquinone CI brief — competitive landscape report
- Menaquinone updates RSS · CI watch RSS
- Cairo University portfolio CI